US2005013827A1PendingUtilityA1

Novel molecules of the herpesvirus-entry-mediator-related protein family and uses thereof

Assignee: MILLENNIUM PHARM INCPriority: Sep 3, 1998Filed: Sep 1, 2004Published: Jan 20, 2005
Est. expirySep 3, 2018(expired)· nominal 20-yr term from priority
A61P 37/08A61P 37/02A61P 31/12A61P 31/10A61P 35/00A61P 29/00G01N 2333/525G01N 33/6863A61P 19/02C07K 14/70578Y02A50/30
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Novel TANGO-69-receptor polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length TANGO-69-receptor proteins, the invention further provides isolated TANGO-69-receptor fusion proteins, antigenic peptides and anti-TANGO-69-receptor antibodies. The invention also provides TANGO-69-receptor nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a TANGO-69-receptor gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

Claims

exact text as granted — not AI-modified
1 . An isolated nucleic acid molecule selected from the group consisting of: 
 a) a nucleic acid molecule comprising a nucleotide sequence which is at least 89.5% identical to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:17, the cDNA insert of the plasmid deposited with ATCC as Accession Number 98821, the cDNA insert of the plasmid deposited with ATCC as Accession Number 207173, or a complement thereof;    b) a nucleic acid molecule comprising a nucleotide sequence which is at least 58% identical to the nucleotide sequence of SEQ ID NO:29, the cDNA insert of the plasmid deposited with ATCC as Accession Number 207172, or a complement thereof;    c) a nucleic acid molecule comprising a nucleotide sequence which is at least 76% identical to the nucleotide sequence of SEQ ID NO:41, the cDNA insert of the plasmid deposited with ATCC as Accession Number 207171, or a complement thereof;    d) a nucleic acid molecule comprising a nucleotide sequence which is at least 70% identical to the nucleotide sequence of SEQ ID NO:3, SEQ ID NO:19, SEQ ID NO:31, or a complement thereof;    e) a nucleic acid molecule comprising a nucleotide sequence which is at least 92% identical to the nucleotide sequence of SEQ ID NO:43, or a complement thereof; and    f) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:20, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98821, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207173, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207172, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207171.    
     
     
         2 . The isolated nucleic acid molecule of  claim 1 , which is selected from the group consisting of: 
 a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:41, SEQ ID NO:43, the cDNA insert of the plasmid deposited with ATCC as Accession Number 98821, the cDNA insert of the plasmid deposited with ATCC as Accession Number 207173, the cDNA insert of the plasmid deposited with ATCC as Accession Number 207172, the cDNA insert of the plasmid deposited with ATCC as Accession Number 207171, or a complement thereof; and    b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:42, SEQ ID NO:44, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98821, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207173, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207172, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207171.    
     
     
         3 . The nucleic acid molecule of  claim 1  further comprising vector nucleic acid sequences.  
     
     
         4 . The nucleic acid molecule of  claim 1  further comprising nucleic acid sequences encoding a heterologous polypeptide.  
     
     
         5 . A host cell which contains the nucleic acid molecule of  claim 1 .  
     
     
         6 . The host cell of  claim 5  which is a mammalian host cell.  
     
     
         7 . A non-human mammalian host cell containing the nucleic acid molecule of  claim 1 .  
     
     
         8 . An isolated polypeptide selected from the group consisting of: 
 a) a polypeptide which is encoded by a nucleic acid molecule comprising a Inucleotide sequence which is at least 70% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:3, SEQ ID NO:19, SEQ ID NO:31, or a complement thereof.    b) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 92% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:43, or a complement thereof; and    c) a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:42, or SEQ ID NO:44.    
     
     
         9 . The isolated polypeptide of  claim 8  comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:42, or SEQ ID NO:44, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98821, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207173, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207172, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207171.  
     
     
         10 . The polypeptide of  claim 8  further comprising heterologous amino acid sequences.  
     
     
         11 . An antibody which selectively binds to a polypeptide of  claim 8 .  
     
     
         12 . A method for producing a polypeptide comprising culturing the host cell of  claim 5  under conditions in which the nucleic acid molecule is expressed.  
     
     
         13 . A method for detecting the presence of a polypeptide of  claim 8  in a sample, comprising: 
 a) contacting the sample with a compound which selectively binds to a polypeptide of  claim 8;  and    b) determining whether the compound binds to the polypeptide in the sample.    
     
     
         14 . The method of  claim 13 , wherein the compound which binds to the polypeptide is an antibody.  
     
     
         15 . A kit comprising a compound which selectively binds to a polypeptide of  claim 8  and instructions for use.  
     
     
         16 . A method for detecting the presence of a nucleic acid molecule of  claim 1  in a sample, comprising the steps of: 
 a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and    b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.    
     
     
         17 . The method of  claim 16 , wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.  
     
     
         18 . A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of  claim 1  and instructions for use.  
     
     
         19 . A method for identifying a compound which binds to a polypeptide of  claim 8  comprising the steps of: 
 a) contacting a polypeptide, or a cell expressing a polypeptide of  claim 8  with a test compound; and    b) determining whether the polypeptide binds to the test compound.    
     
     
         20 . The method of  claim 19 , wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of: 
 a) detection of binding by direct detecting of test compound/polypeptide binding;    b) detection of binding using a competition binding assay;    c) detection of binding using an assay for TANGO-69-receptor-mediated signal transduction.    
     
     
         21 . A method for modulating the activity of a polypeptide of  claim 8  comprising contacting a polypeptide or a cell expressing a polypeptide of  claim 8  with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.  
     
     
         22 . A method for identifying a compound which modulates the activity of a polypeptide of  claim 8 , comprising: 
 a) contacting a polypeptide of  claim 8  with a test compound; and    b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.

Join the waitlist — get patent alerts

Track US2005013827A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.